CORCEPT THERAPEUTICS INC

Corcept Therapeutics (CORT) climbs 3.9% as the tech rally lifts pharma, driven by robust liquidity, a $12B cap and a novel cortisol‑blocking therapy.

Corcept Therapeutics falls 1.76% as investors weigh overvaluation, limited sales, and stiff competition in metabolic‑psychiatric drugs.